LONDON — The limiting factor for successful surgery to transplant retinal pigment epithelium and choroid in patients with retinal degeneration is technique, according to a speaker here.With three clinical trials in progress or ongoing, pioneering work is being done to develop technique, Robert E. MacLaren, FRCOphth, said at the Euretina Congress.According to MacLaren, revascularization is key to RPE choroid transplantation surgery.
A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI).
LONDON — Significantly fewer endophthalmitis events were associated with ranibizumab injections than aflibercept injections among patients with wet age-related macular degeneration, according to a presentation here.The findings of “real-world” endophthalmitis rates between the two licensed treatments for wet AMD “underline the importance of real-world, post-market approval of observational monitoring of novel medicines,” authors Simon P. Kelly and colleagues wrote in a poster presented at the Euretina Congress.
LONDON — Quantel Medical announced the launch of two disposable product lines at the European Society of Cataract and Refractive Surgeons meeting here.The new products include Vitra laser probes and a series of disposable, single-use diagnostic and therapeutic lenses, according to a press release from the company.Two new Vitra designs were introduced: a flexible-tip laser probe and a steerable laser probe. Both designs are compatible with Quantel’s Supra and Vitra multispot laser photocoagulation platforms for the treatment of retinal diseases.
LONDON — Alcon announced the launch of three new products in its line of vitreoretinal surgical instruments at the Euretina Congress, which preceded the European Society of Cataract and Refractive Surgeons meeting here.The product launch includes the Ultravit high-speed vitrectomy probes, 27+ vitrectomy packs with a full range of 27-gauge instrumentation and the Finesse Flex Loop, according to a press release from Alcon.
Northwestern Medicine® scientists have discovered a novel cause of glaucoma in an animal model, and related to their findings, are now developing an eye drop aimed at curing the disease.